4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis

The KRAS mutation is one of the leading driver mutations in colorectal cancer (CRC), and it is usually associated with poor prognosis and drug resistance. Therapies targeting the epidermal growth factor receptor (EFGR) are widely used for end-stage CRC. However, patients with KRAS mutant genes canno...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yi Cheng, Tsai, Tung-Yao, Yadav, Vijesh Kumar, Deng, Li, Huang, Chun-Chih, Tzeng, Yew-Min, Yeh, Chi-Tai, Chen, Ming-Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307961/
https://www.ncbi.nlm.nih.gov/pubmed/34299137
http://dx.doi.org/10.3390/ijms22147508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307961/
https://www.ncbi.nlm.nih.gov/pubmed/34299137
http://dx.doi.org/10.3390/ijms22147508

Ejemplares similares